Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma

Inclusion Criteria: * newly diagnosed GBM * Diagnosis must be established by open biopsy or tumour resection * Tumour must have a supratentorial component * Over 18 years * pre-treatment evaluations must be met * study therapy to begin within 6 weeks of surgery * KPS greater or equal to 70 * patients must sign informed consent * If female, patients must not be pregnant or lactating * Women of childbearing potential and male participants must practice adequate contraception Exclusion Criteria: * prior invasive malignancy )except for non-melanomatous skin cancer) unless disease free for greater than 3 years * recurrent or multifocal malignant gliomas * metastatic disease of leptomeningeal spread * prior chemo or radiosensitizers for cancers of the head and neck region * prior RT to head and neck region except for T1 glottic cancer, resulting in overlap of radiation fields. * Severe active co-morbidity define in protocol * Pregnant of lactating women * Women of childbearing potential or men who are sexually active who are not willing or able to use medically acceptable forms of contraception; this exclusion is necessary due to the treatment involved potentially being teratogenic. * prior allergic reaction to temozolomide and/or dichloroacetate * History of HIV/AIDS